Low-Dose Aspirin Shows Promise for Preventing Colorectal Cancer Recurrence

A targeted approach using aspirin reduces recurrence risk in patients with PI3K pathway mutations

Jan 30, 2025

∙ Paid

A modern, professional medical illustration depicting the positive impact of low-dose aspirin on colorectal cancer recurrence reduction. The image features a stylized DNA strand representing genetic research, alongside a simplified human colon graphic. A subtle overlay of a pill icon symbolizes aspirin's role in treatment. The background conveys an innovative and hopeful tone with soft, clean gradients, ensuring an approachable and visually engaging style.

Key Takeaway

A phase 3 clinical trial revealed that daily low-dose aspirin significantly reduces colorectal cancer (CRC) recurrence in patients with specific genetic mutations in the PI3K signaling pathway.

Understanding the Study

The ALASCCA trial, presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, inves…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.